melanoma

Jan 26, 2021

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Dec 16, 2016

Cancer, a highly morbid disease, has one of the worst incidence and mortality statistics across the globe. As reported by the American Cancer Society, the estimated annual incidence for 2016 has crossed 40,000 cases or more in USA alone. In the statistics, the most common type of cancer is breast cancer, with around...

Apr 13, 2015

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...